Moderna’s updated COVID-19 vaccine, Spikevax JN.1, which targets the JN.1 variant of SARS-CoV-2, has been authorized by the UK's Medicines and Healthcare products Regulatory Agency (MHRA), the company announced on September 3, 2024. The vaccine will be distributed through the NHS autumn vaccination program, with a focus on those who are most susceptible to severe COVID-19-related illnesses. The updated vaccine will be available for private purchase in the UK for the first time, enabling individuals who are not eligible under the NHS scheme to access it through pharmacies, occupational health providers, and private healthcare facilities.
Moderna, a leader in mRNA medicine, is recognized for its pioneering role in the development of COVID-19 vaccines. The updated Spikevax JN.1 vaccine follows recommendations from the World Health Organization to target the JN.1 family of Omicron subvariants, currently dominant in the UK. By utilizing its mRNA platform, Moderna continues to advance innovative therapeutics and vaccines across various disease areas, including infectious and rare diseases, immuno-oncology, and autoimmune conditions. With this latest MHRA approval, Moderna reinforces its commitment to protecting public health and addressing evolving viral threats.
